U.S. markets close in 3 hours 5 minutes
  • S&P 500

    4,689.14
    +97.47 (+2.12%)
     
  • Dow 30

    35,742.92
    +515.89 (+1.46%)
     
  • Nasdaq

    15,702.91
    +477.76 (+3.14%)
     
  • Russell 2000

    2,268.69
    +65.21 (+2.96%)
     
  • Crude Oil

    72.58
    +3.09 (+4.45%)
     
  • Gold

    1,784.20
    +4.70 (+0.26%)
     
  • Silver

    22.52
    +0.26 (+1.15%)
     
  • EUR/USD

    1.1247
    -0.0039 (-0.35%)
     
  • 10-Yr Bond

    1.4600
    +0.0260 (+1.81%)
     
  • GBP/USD

    1.3225
    -0.0036 (-0.27%)
     
  • USD/JPY

    113.7210
    +0.2310 (+0.20%)
     
  • BTC-USD

    51,089.22
    +2,079.04 (+4.24%)
     
  • CMC Crypto 200

    1,316.21
    -5.07 (-0.38%)
     
  • FTSE 100

    7,339.90
    +107.62 (+1.49%)
     
  • Nikkei 225

    28,455.60
    +528.23 (+1.89%)
     

Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Royalty Pharma plc (NASDAQ: RPRX) has acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments.

  • The FDA and European Medicines Agency have approved Oxlumo (EMA) for the treatment of primary hyperoxaluria (PH) type 1 and is marketed by Alnylam Pharmaceuticals Inc (NASDAQ: ALNY).

  • Dicerna became entitled to royalties on worldwide net product sales of Oxlumo as part of a 2020 non-exclusive intellectual property cross-license agreement between Dicerna and Alnylam related to the companies' PH programs.

  • Dicerna is entitled to royalties in the mid to high single digits based on OXLUMO global net sales.

  • This transaction, together with Dicerna's cash, cash equivalents, held-to-maturity investments, and anticipated milestone and other payments from existing collaborations, is expected to extend Dicerna's projected cash runway and be sufficient to fund the execution of its current clinical and operating plan into 2024.

  • Price Action: DRNA shares closed 1.5% lower at $25.75 on Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.